SynthesisBMC cancer2026
Prognostic value of peripheral blood fibrinogen-to-albumin ratio in pancreatic cancer patients: a systematic review and meta-analysis.
Synthesis in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPancreatic cancer (PC) is a highly lethal malignancy with poor prognosis, largely due to late diagnosis and limited therapeutic efficacy. Identifying accessible and reliable prognostic biomarkers is essential for individualized patient management. The fibrinogen-to-albumin ratio (FAR) has emerged as a potential indicator reflecting systemic inflammation and nutritional status.
methodsWe performed a systematic review and meta-analysis of studies assessing FAR in PC patients. Databases including PubMed, Scopus, EMBASE, and the Cochrane Library were searched up to September 2025. Eligible studies reported hazard ratios (HRs) for overall survival (OS) or progression-free survival (PFS). Pooled analyses, subgroup evaluations, sensitivity tests, and publication bias assessments were conducted using standard meta-analytic techniques.
resultsSix retrospective studies encompassing 1,295 patients were included. High FAR was significantly associated with worse OS (HR = 2.26; 95% CI: 1.73–2.96; p < 0.001) and shorter PFS (HR = 1.88; 95% CI: 1.34–2.66; p < 0.001). Subgroup analyses confirmed the prognostic value of FAR across different treatment modalities and cut-off thresholds. Sensitivity analyses and publication bias tests supported the robustness of these findings.
conclusionsHigh FAR is a simple, cost-effective, and reproducible biomarker predicting poor survival in PC, integrating tumor-related inflammation and host nutritional status. FAR may aid in risk stratification and individualized management, though prospective, multicenter studies are needed to validate its clinical utility and clarify underlying mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.